0001640334-19-002627.txt : 20200122 0001640334-19-002627.hdr.sgml : 20200122 20191219125851 ACCESSION NUMBER: 0001640334-19-002627 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20191219 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ARTELO BIOSCIENCES, INC. CENTRAL INDEX KEY: 0001621221 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] IRS NUMBER: 331220924 STATE OF INCORPORATION: NV FISCAL YEAR END: 0831 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 888 PROSPECT STREET, SUITE 210 CITY: LA JOLLA STATE: CA ZIP: 92037 BUSINESS PHONE: 760-943-1689 MAIL ADDRESS: STREET 1: 888 PROSPECT STREET, SUITE 210 CITY: LA JOLLA STATE: CA ZIP: 92037 FORMER COMPANY: FORMER CONFORMED NAME: REACTIVE MEDICAL INC. DATE OF NAME CHANGE: 20170207 FORMER COMPANY: FORMER CONFORMED NAME: KNIGHT KNOX DEVELOPMENT CORP. DATE OF NAME CHANGE: 20141001 CORRESP 1 filename1.htm artl_acletter.htm

 

 

December 19, 2019

 

Via EDGAR

 

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549-3720

 

 Attention:

 

Daniel Morris

 

 

 

 Re:

 

Artelo Biosciences, Inc.

 

 

Registration Statement on Form S-3

 

 

Filed on November 25, 2019

 

 

File No. 333-234372

  

 

 

Acceleration Request

 

 

 

Requested Date:

December 20, 2019

 

 

Requested Time:

4:00 P.M. Eastern Time

 

Ladies and Gentlemen:

 

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Artelo Biosciences, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-3 (File No. 333-234372) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable, or at such later time as the Company or its counsel may request via telephone call to the staff of the Division of Corporation Finance (the “Staff”) of the Securities and Exchange Commission (the “Commission”). The Company hereby authorizes Thomas Hornish of Wilson Sonsini Goodrich & Rosati, Professional Corporation, counsel for the Company, to make such request on the Company’s behalf.

 

The Company acknowledges that should the Commission or its Staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing. In addition, the Company acknowledges that the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing. Finally, the Company acknowledges that it may not assert the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

 

The Company requests that it be notified of the effectiveness of the Registration Statement by telephone to Thomas Hornish of Wilson Sonsini Goodrich & Rosati, Professional Corporation at (858) 350-2392 or via email at thornish@wsgr.com.  If notice of effectiveness is given by telephone, please also provide a copy of the Commission’s order declaring the Registration Statement effective to Thomas Hornish via facsimile at (858) 350-2399.

 

 

 
 
 
 

 

Securities and Exchange Commission

Re: Artelo Biosciences, Inc.

December 18, 2019

Page 2

 

 

Please direct any questions or comments regarding this acceleration request to Thomas Hornish at (858) 350-2392.

 

 

Sincerely,

 

ARTELO BIOSCIENCES, INC.

 

 

By:

/s/ Gregory D. Gorgas

 

Gregory D. Gorgas

 

President and Chief Executive Officer

 

 

cc:

Thomas E. Hornish, Esq.

Mahnaz Daruwalla, Esq.

Wilson Sonsini Goodrich & Rosati, Professional Corporation